Clinical trials: Neoplasia Prostate
Prostate Cancer
Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Calcitriol may help carboplatin kill more cancer cells by making tumor cells more sensitive to the drug.
- Trial name
- NCT00017576
- Testing
- calcitriol, carboplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
Whole Body Bone Scan vs 18F-Choline PET/CT in Prostate Cancer
Prostate cancer is currently the leading newly diagnosed cancer in the industrialized world. Treatment of prostate cancer is highly dependent on the stage of the disease. Current methods for staging are known to be inaccurate.
- Trial name
- NCT02232685
- Testing
- 18F-Choline PET/CT
- Where
- Denmark
- Volunteers
- 143 people
- Sponsor
- Odense University Hospital
Prostate Cancer
CivaSheet With Radical Prostatectomy & Adjuvant External Beam Radiation
A phase I single-arm open label dose escalation study to evaluate the maximum tolerated dose (MTD) and safety of Civasheet® with radical prostatectomy (RP) and adjuvant external beam radiation therapy (EBRT) in a 3+3 dose…
- Trial name
- NCT03657108
- Testing
- Civasheet 60 Gy, Civasheet 75 Gy, Adjuvant external beam radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Castration-Resistant Prostatic Cancer
Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
This observational prospective single arm cohort study is designed to assess pain and bone pain related quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium-223 in a real life…
- Trial name
- PARABO (NCT02398526)
- Testing
- Radium-223 dichloride, (Xofigo, BAY88-8223)
- Where
- Germany
- Volunteers
- 363 people
- Sponsor
- Bayer
Prostate Cancer
Hybrid Intelligence for Trustable Diagnosis and Patient Management of Prostate Cancer (HIT-PIRADS)
The purpose of this study is to develop a new way to diagnose prostate cancer through the use of artificial intelligence. The goal is for this new method to reduce delays in diagnoses and to avoid invasive procedures such as…
- Trial name
- HIT-PIRADS (NCT06804785)
- Where
- United States
- Sponsor
- Northwestern University
Prostate Cancer
Use of Multi-Parametric MRI With Prostate Biopsy for Cancer Diagnosis.
This is a prospective single center trial to examine the rates of cancer diagnosis when using computerized software to target suspicious lesions within the prostate identified on mpMRI.
- Trial name
- NCT01964638
- Testing
- Targeted Biopsy
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- NYU Langone Health
Pain Management, Opioid Use
Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy
The objective of this study is to conduct a randomized clinical trial to evaluate an opioid versus an opioid-free pathway of perioperative use of ketamine, ketorolac, and IV acetaminophen followed by the postoperative use of…
- Conditions
- Pain Management, Opioid Use, Prostate Cancer
- Trial name
- NCT05597878
- Testing
- Oxycodone, Acetaminophen, Ketamine
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Wake Forest University Health Sciences
Cancer
Heuristics, Algorithms and Machine Learning: Evaluation & Testing in Radiation Therapy
The Hamlet.rt study is a prospective data collection and patient questionnaire study for patients undergoing image-guided radiotherapy with curative intent.
- Trial name
- Hamlet rt (NCT04060706)
- Testing
- Radical Image-Guided Radiotherapy
- Where
- United Kingdom
- Volunteers
- 310 people
- Sponsor
- CCTU- Cancer Theme
Prostate Tumors
MR-Guided Laser Ablation of Prostate Bed Recurrences
The purpose of this study is to see if MR-guided laser ablation can effectively treat prostate tumor recurrences.
- Trial name
- NCT01743638
- Testing
- MR-Guided Laser Ablation
- Where
- United States
- Sponsor
- Mayo Clinic
Prostate Cancer
Open-label Extension Study of the Effects of Pomegranate Extract on Rising PSA After Primary Therapy for Prostate Cancer
This study is an open-label extension to the double-blind GUP-0205-1 and double-blind extension GUP-0205-1XX studies. High concentrations of anti-oxidants in pomegranate seeds present a potential strategy to delay clinical…
- Trial name
- NCT00731848
- Testing
- pomegranate liquid extract
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Roll International Corporation
Recurrent Prostate Cancer
Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
This randomized phase II trial is studying how well pazopanib hydrochloride works after leuprolide or goserelin in treating patients with relapsed prostate cancer.
- Trial name
- NCT00454571
- Testing
- pazopanib hydrochloride, leuprolide acetate, goserelin acetate
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer
This is a phase I neoadjuvant gene therapy followed by prostatectomy, open-label, dose-escalation trial for prostate cancer patients with high risk of local recurrence after radical prostatectomy.
- Trial name
- NCT01197209
- Testing
- Ad-REIC/Dkk-3
- Where
- United States
- Sponsor
- Momotaro-Gene Inc.
Prostate Cancer
Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients
This is a multi-center, open-label study of 2 doses of leuprolide acetate 17 mg depot, administered three months apart, in subjects with prostate cancer who might benefit from medical androgen deprivation therapy
- Trial name
- NCT00630799
- Testing
- leuprolide acetate
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- GP-Pharm
Prostate Cancer
Positron Emission Radiomics With PSMA Radioligands on Newly Diagnosed Prostate Cancer Patients
The primary aim of this large prospective study consists of exploring the correlation among Volumetric and Radiomic parameters extracted from staging PSMA PET/CT Imaging versus conventional baseline clinical biochemical data…
- Trial name
- PER2PSMA (NCT05819606)
- Testing
- Immunohistochemistry (IHC) analysis
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two different treatment combinations of tulmimetostat in participants with de novo or recurrent metastatic hormone-sensitive prostate cancer…
- Trial name
- TulmiSTAR-02 (NCT07190300)
- Testing
- Tulmimetostat, Darolutamide, Abiraterone
- Where
- 31 sites in United States, Australia and 12 more
- Volunteers
- 181 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma, Prostate Cancer
An Expanded Access Program for AM0010 (Pegilodecakin)
This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- NCT03554434
- Testing
- AM0010
- Sponsor
- Eli Lilly and Company
Prostate Cancer
Validation of a Machine Learning Model Based on MR for the Prediction of Prostate Cancer
The goal of this observational study is to validate a clinically significant predictive machine learning model based on the processing of images RMmp (Multiparametric Magnetic Resonance Imaging).
- Trial name
- NCT06773598
- Where
- Italy
- Volunteers
- 1,100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Neoplasms, Prostate
A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
This study aims to evaluate how well risvutatug rezetecan (Ris-Rez) works in treating prostate cancer compared to best supportive/standard of care (BSC) which may include a hormone therapy with an androgen receptor pathway…
- Trial name
- NCT07802704
- Testing
- Risvutatug rezetecan (Ris-Rez), Enzalutamide, Abiraterone
- Where
- 6 sites in Australia, Canada and 2 more
- Volunteers
- 684 people
- Sponsor
- GlaxoSmithKline
Metastatic Prostate Cancer
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants…
- Trial name
- IPATential150 (NCT03072238)
- Testing
- Ipatasertib, Abiraterone, Prednisone/Prednisolone
- Where
- 176 sites in United States, Australia and 24 more
- Volunteers
- 1,101 people
- Sponsor
- Hoffmann-La Roche
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.